HMS Networks AB (publ) completes repurchase of shares

HMS Networks AB (publ) has during the period February 23, 2024 – March 7, 2024, repurchased in total 25,000 own shares (ISIN SE0009997018) within the buyback program initiated by the Board of Directors in order to secure HMS’ obligations to deliver performance shares according to HMS’ Share Saving Plan. The weighted average price for the shares repurchased during the period amounts to SEK 449.02 per share.

HMS Networks’ holdings of own shares amounts to 143,416 after the repurchase. The total number of outstanding shares in the company is 46,818,868. The repurchase has been made on Nasdaq Stockholm.

For more information, please contact:
Staffan Dahlström, CEO HMS, +46 (0)35 17 29 01
Joakim Nideborn, CFO HMS, +46 (0)35 710 6983

HMS Networks AB (publ) is a market-leading provider of solutions in industrial information and communication technology (Industrial ICT). HMS develops and manufactures products under the Anybus®, Ixxat®, Ewon® and Intesis® brands. Development takes place at the headquarter in Halmstad and also in Ravensburg, Nivelles, Igualada, Wetzlar, Buchen, Delft, Sibiu, Rotterdam and Bilbao. Local sales and support are handled by branch offices in Germany, USA, Japan, China, Singapore, Italy, France, Spain, the Netherlands, India, UK, Sweden, South Korea, Australiac UAE and Vietnam, as well as through a worldwide network of distributors and partners. HMS employs over 800 people and reported sales of SEK 3,025 million in 2023. HMS is listed on the NASDAQ OMX in Stockholm in the Large Cap segment and Telecommunications sector.

Attachment

• PRM - HMS completes repurchase of shares

You May Also Be Interested In

• Crypto News Today: AlphaPepe Presale Stage 20 Sold Out While Ethereum Price Prediction Targets $12,000
• Zcash Price Prediction: ZEC Targets $1,750 as AlphaPepe Counts Down to a New CEX Reveal Within Two Weeks
• Innovent Announces Expansion of Global Phase 3 MarsLight-11 Study of IBI363/TAK-928 (Alpha-biased IL-2/PD-1 Bispecific Fusion Protein) in Immunotherapy-Resistant NSCLC to Include Patients with Non-Squ